Literature DB >> 34001963

TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features.

António Castanheira1,2, Maria João Vieira3,4, Mafalda Pinto3,4, Carolina Dias3,4, Luísa Prada3,4,5, Sofia Macedo3,4, Margarida Sá Fernandes6, Fortunato Vieira7, Paula Soares2,3,4, Alberto Mota2,8, José Manuel Lopes2,3,4,6, Paula Boaventura9,10,11.   

Abstract

Cutaneous basal cell carcinoma (cBCC) is an economic burden to health services, due to its great morbidity and increasing incidence in old people. Infiltrative cBCCs and cBCCs with micronodular pattern are considered as more aggressive. The role of p53 expression and TERTp mutation on cBCC behavior remains to be clarified. We aimed to assess TERTp mutations and p53 expression in relation to the cBCC histological subtype in a cohort of patients referred to an ENT Department of a tertiary Hospital of Northern Portugal. We performed a retrospective clinicopathological and histological review of the head and neck cBCCs followed-up at the otorhinolaryngology department of Trás-os-Montes e Alto Douro hospital (January 2007-June 2018). We assessed TERTp mutations in 142 cBCCs and p53 protein expression, through immunohistochemistry, in 157 cBCCs. We detected TERTp mutations in 43.7% of cBCCs and p53 overexpression in 60.5% of cBCCs. We spotted association of p53 overexpression and TERTp mutation with necrosis. In the infitrative-growth pattern cBCCs, there was no significant association with the clinical and histological features evaluated, except for necrosis. In the indolent-growth cBCCs, we identified a significant association of TERTp mutation status with female sex, necrosis, multiple cBCCs, and p53 positive expression. Our results suggest that TERTp mutation may be useful to identify more aggressive features in the indolent-growth pattern cBCCs (nodular and superficial subtypes). Further studies with larger cohorts are warranted to clarify the relevance of TERTp mutation in cBCCs.

Entities:  

Year:  2021        PMID: 34001963     DOI: 10.1038/s41598-021-89906-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  37 in total

1.  p53 expression related to the aggressive infiltrative histopathological feature of basal cell carcinoma.

Authors:  Sauvarat Auepemkiate; P Boonyaphiphat; P Thongsuksai
Journal:  Histopathology       Date:  2002-06       Impact factor: 5.087

Review 2.  Basal cell carcinoma: biology, morphology and clinical implications.

Authors:  A Neil Crowson
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

3.  S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik.

Authors:  Berenice M Lang; Panagiotis Balermpas; Andrea Bauer; Andreas Blum; G Felix Brölsch; Thomas Dirschka; Markus Follmann; Jorge Frank; Bernhard Frerich; Klaus Fritz; Axel Hauschild; Ludwig M Heindl; Hans-Peter Howaldt; Stephan Ihrler; Vinodh Kakkassery; Bernhard Klumpp; Albrecht Krause-Bergmann; Christoph Löser; Markus Meissner; Michael M Sachse; Max Schlaak; Michael P Schön; Lutz Tischendorf; Michael Tronnier; Dirk Vordermark; Julia Welzel; Michael Weichenthal; Susanne Wiegand; Roland Kaufmann; Stephan Grabbe
Journal:  J Dtsch Dermatol Ges       Date:  2019-01       Impact factor: 5.584

4.  Immunoexpression of p53 and COX-2 in basal cell carcinoma.

Authors:  Andreea Oana Enache; Alex Emilian Stepan; Claudiu Mărgăritescu; Virgil Pătraşcu; Raluca Niculina Ciurea; Cristiana Eugenia Simionescu; Adrian Camen
Journal:  Rom J Morphol Embryol       Date:  2018       Impact factor: 1.033

Review 5.  Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Authors:  Ketty Peris; Maria Concetta Fargnoli; Claus Garbe; Roland Kaufmann; Lars Bastholt; Nicole Basset Seguin; Veronique Bataille; Veronique Del Marmol; Reinhard Dummer; Catherine A Harwood; Axel Hauschild; Christoph Höller; Merete Haedersdal; Josep Malvehy; Mark R Middleton; Colin A Morton; Eduardo Nagore; Alexander J Stratigos; Rolf-Markus Szeimies; Luca Tagliaferri; Myrto Trakatelli; Iris Zalaudek; Alexander Eggermont; Jean Jacques Grob
Journal:  Eur J Cancer       Date:  2019-07-06       Impact factor: 9.162

Review 6.  Epidemiology of basal cell carcinoma: scholarly review.

Authors:  J A C Verkouteren; K H R Ramdas; M Wakkee; T Nijsten
Journal:  Br J Dermatol       Date:  2017-02-20       Impact factor: 9.302

7.  Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.

Authors:  Habib Ansarin; Mina Daliri; Razieh Soltani-Arabshahi
Journal:  Eur J Dermatol       Date:  2006 Sep-Oct       Impact factor: 3.328

8.  p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.

Authors:  Svetlana Bolshakov; Christopher M Walker; Sara S Strom; Mano S Selvan; Gary L Clayman; Adel El-Naggar; Scott M Lippman; Margaret L Kripke; Honnavara N Ananthaswamy
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

9.  Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas.

Authors:  Resit D Koseoglu; Engin Sezer; Ahmet Eyibilen; Ibrahim Aladag; Ilker Etikan
Journal:  J Cutan Pathol       Date:  2009-09       Impact factor: 1.587

Review 10.  Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes.

Authors:  Tiago Ribeiro Correia de Sá; Roberto Silva; José Manuel Lopes
Journal:  Future Oncol       Date:  2015-10-09       Impact factor: 3.404

View more
  2 in total

1.  Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

Authors:  Gino Kim In; Aparna Nallagangula; Jacob Seung Choi; Lisa Tachiki; Matthew J Blackburn; Stephen Capone; Kathryn B Bollin; Daniel Y Reuben; Keisuke Shirai; Sandy Zhang-Nunes; Omar Ragab; Alicia Terando; Jenny C Hu; Han Lee; Shailender Bhatia; Sunandana Chandra; Jose Lutzky; Geoffrey Thomas Gibney
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 2.  Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.

Authors:  Toshihiko Hoashi; Naoko Kanda; Hidehisa Saeki
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.